Table of Contents Author Guidelines Submit a Manuscript
Table of Contents Alerts

To receive news and publication updates for Mediators of Inflammation, enter your email address in the box below.

Mediators of Inflammation
Volume 2017 (2017), Article ID 9673537, 21 pages
https://doi.org/10.1155/2017/9673537
Review Article

Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation

Marcia L. Moss1 and Dmitry Minond2,3

1Verra Therapeutics, 127 Asbury Rd., Lansing, NY 14882, USA
2Rumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR 6th Floor, Fort Lauderdale, FL 33328, USA
3College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33328, USA

Correspondence should be addressed to Marcia L. Moss; moc.liamg@0tsitneicsssom

Received 4 July 2017; Revised 15 August 2017; Accepted 11 September 2017; Published 2 November 2017

Academic Editor: Vera L. Petricevich

Copyright © 2017 Marcia L. Moss and Dmitry Minond. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Dreymueller, S. Uhlig, and A. Ludwig, “ADAM-family metalloproteinases in lung inflammation: potential therapeutic targets,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 308, no. 4, pp. L325–L343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. J. Pruessmeyer and A. Ludwig, “The good, the bad and the ugly substrates for ADAM10 and ADAM17 in brain pathology, inflammation and cancer,” Seminars in Cell & Developmental Biology, vol. 20, no. 2, pp. 164–174, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Weber and P. Saftig, “Ectodomain shedding and ADAMs in development,” Development, vol. 139, no. 20, pp. 3693–3709, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. D. R. Edwards, M. M. Handsley, and C. J. Pennington, “The ADAM metalloproteinases,” Molecular Aspects of Medicine, vol. 29, no. 5, pp. 258–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Gooz, “ADAM-17: the enzyme that does it all,” Critical Reviews in Biochemistry and Molecular Biology, vol. 45, no. 2, pp. 146–169, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. L. Moss, S. L. Jin, M. E. Milla et al., “Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α,” Nature, vol. 385, no. 6618, pp. 733–736, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. R. A. Black, C. T. Rauch, C. J. Kozlosky et al., “A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells,” Nature, vol. 385, no. 6618, pp. 729–733, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. M. J. Duffy, J. Crown, and M. Mullooly, “ADAM10 and ADAM17: new players in trastuzumab resistance,” Oncotarget, vol. 5, no. 22, pp. 10963-10964, 2014. View at Publisher · View at Google Scholar
  9. A. M. Lee and R. B. Diasio, “ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?” Clinical Cancer Research, vol. 16, no. 13, pp. 3319–3321, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. N. Kyula, S. Van Schaeybroeck, J. Doherty, C. S. Fenning, D. B. Longley, and P. G. Johnston, “Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer,” Clinical Cancer Research, vol. 16, no. 13, pp. 3378–3389, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. S. M. Le Gall, T. Maretzky, P. D. Issuree et al., “ADAM17 is regulated by a rapid and reversible mechanism that controls access to its catalytic site,” Journal of Cell Science, vol. 123, no. 22, pp. 3913–3922, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Sommer, F. Kordowski, J. Buch et al., “Phosphatidylserine exposure is required for ADAM17 sheddase function,” Nature Communications, vol. 7, article 11523, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. G. M. McGeehan, J. D. Becherer, R. C. Bast Jr. et al., “Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor,” Nature, vol. 370, no. 6490, pp. 558–561, 1994. View at Publisher · View at Google Scholar
  14. M. L. Moss, L. Sklair-Tavron, and R. Nudelman, “Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis,” Nature Clinical Practice Rheumatology, vol. 4, no. 6, pp. 300–309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Gearing, P. Beckett, M. Christodoulou et al., “Processing of tumour necrosis factor-α precursor by metalloproteinases,” Nature, vol. 370, no. 6490, pp. 555–557, 1994. View at Publisher · View at Google Scholar
  16. J. G. Conway, R. C. Andrews, B. Beaudet et al., “Inhibition of tumor necrosis factor-α (TNF-α) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-α-converting enzyme and matrix metalloproteinases,” The Journal of Pharmacology and Experimental Therapeutics, vol. 298, no. 3, pp. 900–908, 2001. View at Google Scholar
  17. M. H. Rabinowitz, R. C. Andrews, J. D. Becherer et al., “Design of selective and soluble inhibitors of tumor necrosis factor-α converting enzyme (TACE)+,” Journal of Medicinal Chemistry, vol. 44, no. 24, pp. 4252–4267, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. L. Witters, P. Scherle, S. Friedman et al., “Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor,” Cancer Research, vol. 68, no. 17, pp. 7083–7089, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Wong, T. Cohen, E. Romi et al., “Harnessing the natural inhibitory domain to control TNFα converting enzyme (TACE) activity in vivo,” Scientific Reports, vol. 6, article 35598, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Jinushi, T. Takehara, T. Kanto et al., “Critical role of MHC class I-related chain A and B expression on IFN-α-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C virus infection,” The Journal of Immunology, vol. 170, no. 3, pp. 1249–1256, 2003. View at Publisher · View at Google Scholar
  21. G. Chitadze, M. Lettau, J. Bhat et al., “Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17,” International Journal of Cancer, vol. 133, no. 7, pp. 1557–1566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. I. Waldhauer, D. Goehlsdorf, F. Gieseke et al., “Tumor-associated MICA is shed by ADAM proteases,” Cancer Research, vol. 68, no. 15, pp. 6368–6376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. V. Rebmann, P. Schutt, D. Brandhorst et al., “Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients,” Clinical Immunology, vol. 123, no. 1, pp. 114–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Holdenrieder, P. Stieber, A. Peterfi, D. Nagel, A. Steinle, and H. R. Salih, “Soluble MICA in malignant diseases,” International Journal of Cancer, vol. 118, no. 3, pp. 684–687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Romee, B. Foley, T. Lenvik et al., “NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17),” Blood, vol. 121, no. 18, pp. 3599–3608, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Lajoie, N. Congy-Jolivet, A. Bolzec et al., “ADAM17-mediated shedding of FcγRIIIA on human NK cells: identification of the cleavage site and relationship with activation,” The Journal of Immunology, vol. 192, no. 2, pp. 741–751, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Seyfizadeh, N. Seyfizadeh, J. Hasenkamp, and S. Huerta-Yepez, “A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections,” Critical Reviews in Oncology/Hematology, vol. 97, pp. 275–290, 2016. View at Publisher · View at Google Scholar · View at Scopus
  28. R. C. Newton, E. C. Bradley, R. S. Levy et al., “Clinical benefit of INCB7839, a potent and selective ADAM inhibitor, in combination with trastuzumab in patients with metastatic HER2+ breast cancer,” Journal of Clinical Oncology, vol. 28, 15_Supplement, pp. 3025–3025, 2010. View at Publisher · View at Google Scholar
  29. K. Moller-Hackbarth, C. Dewitz, O. Schweigert et al., “A disintegrin and metalloprotease (ADAM) 10 and ADAM17 are major sheddases of T cell immunoglobulin and mucin domain 3 (Tim-3),” The Journal of Biological Chemistry, vol. 288, no. 48, pp. 34529–34544, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Ocana-Guzman, L. Torre-Bouscoulet, and I. Sada-Ovalle, “TIM-3 regulates distinct functions in macrophages,” Frontiers in Immunology, vol. 7, p. 229, 2016. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Monney, C. A. Sabatos, J. L. Gaglia et al., “Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease,” Nature, vol. 415, no. 6871, pp. 536–541, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. T. Hoashi, K. Tamaki, and V. J. Hearing, “The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding,” FASEB Journal, vol. 24, no. 3, pp. 916–930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Kawaguchi, Y. Hozumi, and T. Suzuki, “ADAM protease inhibitors reduce melanogenesis by regulating PMEL17 processing in human melanocytes,” Journal of Dermatological Science, vol. 78, no. 2, pp. 133–142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. D. J. Schwartzentruber, D. H. Lawson, J. M. Richards et al., “gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma,” The New England Journal of Medicine, vol. 364, no. 22, pp. 2119–2127, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. D. Yacoub, N. Benslimane, L. Al-Zoobi, G. Hassan, A. Nadiri, and W. Mourad, “CD154 is released from T-cells by a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) and ADAM17 in a CD40 protein-dependent manner,” The Journal of Biological Chemistry, vol. 288, no. 50, pp. 36083–36093, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. A. W. Tong, M. H. Papayoti, G. Netto et al., “Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer,” Clinical Cancer Research, vol. 7, no. 3, pp. 691–703, 2001. View at Google Scholar
  37. G. S. Hassan, J. Stagg, and W. Mourad, “Role of CD154 in cancer pathogenesis and immunotherapy,” Cancer Treatment Reviews, vol. 41, no. 5, pp. 431–440, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. I. S. Grewal and R. A. Flavell, “CD40 and CD154 in cell-mediated immunity,” Annual Review of Immunology, vol. 16, pp. 111–135, 1998. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Peng, S. Guo, N. Yin et al., “Ectodomain shedding of Fcα receptor is mediated by ADAM10 and ADAM17,” Immunology, vol. 130, no. 1, pp. 83–91, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. J. E. Bakema, S. H. Ganzevles, D. M. Fluitsma et al., “Targeting FcαRI on polymorphonuclear cells induces tumor cell killing through autophagy,” The Journal of Immunology, vol. 187, no. 2, pp. 726–732, 2011. View at Publisher · View at Google Scholar · View at Scopus
  41. J. E. Bakema and M. van Egmond, “The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity,” Mucosal Immunology, vol. 4, no. 6, pp. 612–624, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Franke, J. Schroder, N. Monhasery et al., “Human and murine interleukin 23 receptors are novel substrates for a disintegrin and metalloproteases ADAM10 and ADAM17,” The Journal of Biological Chemistry, vol. 291, no. 20, pp. 10551–10561, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Okazaki, M. H. Wang, P. Rawsthorne et al., “Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohnʼs disease risk in a population-based case-control study: Evidence of gene–gene interactions,” Inflammatory Bowel Diseases, vol. 14, no. 11, pp. 1528–1541, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. J. L. Langowski, X. Zhang, L. Wu et al., “IL-23 promotes tumour incidence and growth,” Nature, vol. 442, no. 7101, pp. 461–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Bartkowiak and M. A. Curran, “4-1BB agonists: multi-potent potentiators of tumor immunity,” Frontiers in Oncology, vol. 5, p. 117, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. M. A. Nielsen, T. Andersen, A. Etzerodt et al., “A disintegrin and metalloprotease-17 and galectin-9 are important regulators of local 4-1BB activity and disease outcome in rheumatoid arthritis,” Rheumatology, vol. 55, no. 10, pp. 1871–1879, 2016. View at Publisher · View at Google Scholar · View at Scopus
  47. M. L. Moss, J. M. White, M. H. Lambert, and R. C. Andrews, “TACE and other ADAM proteases as targets for drug discovery,” Drug Discovery Today, vol. 6, no. 8, pp. 417–426, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. F. M. Richards, C. J. Tape, D. I. Jodrell, and G. Murphy, “Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo,” PLoS One, vol. 7, no. 7, article e40597, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Uchikawa, M. Yoda, T. Tohmonda et al., “ADAM17 regulates IL-1 signaling by selectively releasing IL-1 receptor type 2 from the cell surface,” Cytokine, vol. 71, no. 2, pp. 238–245, 2015. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Okamura, E. Kohmura, and T. Yamashita, “TACE cleaves neogenin to desensitize cortical neurons to the repulsive guidance molecule,” Neuroscience Research, vol. 71, no. 1, pp. 63–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Konig, D. Gatidou, T. Granja, J. Meier, P. Rosenberger, and V. Mirakaj, “The axonal guidance receptor neogenin promotes acute inflammation,” PLoS One, vol. 7, no. 3, article e32145, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. V. Mirakaj, C. Jennewein, K. Konig, T. Granja, and P. Rosenberger, “The guidance receptor neogenin promotes pulmonary inflammation during lung injury,” FASEB Journal, vol. 26, no. 4, pp. 1549–1558, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. Y. Tanino, M. Y. Chang, X. Wang et al., “Syndecan-4 regulates early neutrophil migration and pulmonary inflammation in response to lipopolysaccharide,” American Journal of Respiratory Cell and Molecular Biology, vol. 47, no. 2, pp. 196–202, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Santoso, T. Kikuchi, N. Tode et al., “Syndecan 4 mediates Nrf2-dependent expansion of bronchiolar progenitors that protect against lung inflammation,” Molecular Therapy, vol. 24, no. 1, pp. 41–52, 2016. View at Publisher · View at Google Scholar · View at Scopus
  55. T. Polte, S. Petzold, J. Bertrand et al., “Critical role for syndecan-4 in dendritic cell migration during development of allergic airway inflammation,” Nature Communications, vol. 6, p. 7554, 2015. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Pruessmeyer, C. Martin, F. M. Hess et al., “A disintegrin and metalloproteinase 17 (ADAM17) mediates inflammation-induced shedding of syndecan-1 and -4 by lung epithelial cells,” The Journal of Biological Chemistry, vol. 285, no. 1, pp. 555–564, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. J. E. Italiano Jr., A. T. Mairuhu, and R. Flaumenhaft, “Clinical relevance of microparticles from platelets and megakaryocytes,” Current Opinion in Hematology, vol. 17, no. 6, pp. 578–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Boilard, P. A. Nigrovic, K. Larabee et al., “Platelets amplify inflammation in arthritis via collagen-dependent microparticle production,” Science, vol. 327, no. 5965, pp. 580–583, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Bender, S. Hofmann, D. Stegner et al., “Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases,” Blood, vol. 116, no. 17, pp. 3347–3355, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. E. E. Gardiner, D. Karunakaran, Y. Shen, J. F. Arthur, R. K. Andrews, and M. C. Berndt, “Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases,” Journal of Thrombosis and Haemostasis, vol. 5, no. 7, pp. 1530–1537, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Young, X. Yu, K. Wolslegel et al., “Lymphotoxin-αβ heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis,” Cytokine, vol. 51, no. 1, pp. 78–86, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. J. L. Browning, I. Dougas, A. Ngam-ek et al., “Characterization of surface lymphotoxin forms. Use of specific monoclonal antibodies and soluble receptors,” The Journal of Immunology, vol. 154, no. 1, pp. 33–46, 1995. View at Google Scholar
  63. I. Gramaglia, D. N. Mauri, K. T. Miner, C. F. Ware, and M. Croft, “Lymphotoxin αβ is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation,” The Journal of Immunology, vol. 162, no. 3, pp. 1333–1338, 1999. View at Google Scholar
  64. Y. F. Chen, P. Jobanputra, P. Barton et al., “A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness,” Health Technology Assessment, vol. 10, no. 42, 2006. View at Publisher · View at Google Scholar
  65. J. J. Peschon, J. L. Slack, P. Reddy et al., “An essential role for ectodomain shedding in mammalian development,” Science, vol. 282, no. 5392, pp. 1281–1284, 1998. View at Publisher · View at Google Scholar
  66. S. W. Sunnarborg, C. L. Hinkle, M. Stevenson et al., “Tumor necrosis factor-α converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability,” The Journal of Biological Chemistry, vol. 277, no. 15, pp. 12838–12845, 2002. View at Publisher · View at Google Scholar · View at Scopus
  67. D. C. Lee, S. W. Sunnarborg, C. L. Hinkle et al., “TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase,” Annals of the New York Academy of Sciences, vol. 995, pp. 22–38, 2003. View at Publisher · View at Google Scholar
  68. U. Sahin and C. P. Blobel, “Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17,” FEBS Letters, vol. 581, no. 1, pp. 41–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  69. U. Sahin, G. Weskamp, K. Kelly et al., “Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands,” The Journal of Cell Biology, vol. 164, no. 5, pp. 769–779, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. B. C. Dickson, A. M. Mulligan, H. Zhang et al., “High-level JAG1 mRNA and protein predict poor outcome in breast cancer,” Modern Pathology, vol. 20, no. 6, pp. 685–693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. A. D. Steg, A. A. Katre, B. Goodman et al., “Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer,” Clinical Cancer Research, vol. 17, no. 17, pp. 5674–5685, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Lu, X. Ye, F. Fan et al., “Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1,” Cancer Cell, vol. 23, no. 2, pp. 171–185, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Coglievina, C. Guarnaccia, V. Zlatev, S. Pongor, and A. Pintar, “Jagged-1 juxtamembrane region: biochemical characterization and cleavage by ADAM17 (TACE) catalytic domain,” Biochemical and Biophysical Research Communications, vol. 432, no. 4, pp. 666–671, 2013. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Aikawa, C. A. Whipple, M. E. Lopez et al., “Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells,” The Journal of Clinical Investigation, vol. 118, no. 1, pp. 89–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. J. Kleeff, T. Ishiwata, A. Kumbasar et al., “The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer,” The Journal of Clinical Investigation, vol. 102, no. 9, pp. 1662–1673, 1998. View at Publisher · View at Google Scholar
  76. R. Kawahara, D. C. Granato, S. Yokoo, R. R. Domingues, D. M. Trindade, and A. F. Leme, “Mass spectrometry-based proteomics revealed glypican-1 as a novel ADAM17 substrate,” Journal of Proteomics, vol. 151, 2017. View at Publisher · View at Google Scholar
  77. J. Malapeira, C. Esselens, J. J. Bech-Serra, F. Canals, and J. Arribas, “ADAM17 (TACE) regulates TGFβ signaling through the cleavage of vasorin,” Oncogene, vol. 30, no. 16, pp. 1912–1922, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. M. Dong, T. How, K. C. Kirkbride et al., “The type III TGF-β receptor suppresses breast cancer progression,” The Journal of Clinical Investigation, vol. 117, no. 1, pp. 206–217, 2007. View at Publisher · View at Google Scholar · View at Scopus
  79. D. Li, D. A. Collier, and L. He, “Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia,” Human Molecular Genetics, vol. 15, no. 12, pp. 1995–2002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  80. J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella, “Neuregulins and cancer,” Clinical Cancer Research, vol. 14, no. 11, pp. 3237–3241, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. E. A. Ebbing, J. P. Medema, H. Damhofer et al., “ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3,” Oncotarget, vol. 7, no. 9, pp. 10243–10254, 2016. View at Publisher · View at Google Scholar · View at Scopus
  82. D. Fleck, F. van Bebber, A. Colombo et al., “Dual cleavage of neuregulin 1 type III by BACE1 and ADAM17 liberates its EGF-like domain and allows paracrine signaling,” The Journal of Neuroscience, vol. 33, no. 18, pp. 7856–7869, 2013. View at Publisher · View at Google Scholar · View at Scopus
  83. E. de Alava, A. Ocana, M. Abad et al., “Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 25, no. 19, pp. 2656–2663, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Shvartsur and B. Bonavida, “Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications,” Genes & Cancer, vol. 6, no. 3-4, pp. 84–105, 2015. View at Publisher · View at Google Scholar
  85. M. Trerotola, P. Cantanelli, E. Guerra et al., “Upregulation of Trop-2 quantitatively stimulates human cancer growth,” Oncogene, vol. 32, no. 2, pp. 222–233, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Lin, H. Zhang, J. Wang et al., “A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo,” International Journal of Cancer, vol. 134, no. 5, pp. 1239–1249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  87. T. M. Wanger, S. Dewitt, A. Collins, N. J. Maitland, Z. Poghosyan, and V. Knauper, “Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17,” Cellular Signalling, vol. 27, no. 7, pp. 1325–1335, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Benej, S. Pastorekova, and J. Pastorek, “Carbonic anhydrase IX: regulation and role in cancer,” Subcellular Biochemistry, vol. 75, pp. 199–219, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Zatovicova, O. Sedlakova, E. Svastova et al., “Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17,” British Journal of Cancer, vol. 93, no. 11, pp. 1267–1276, 2005. View at Publisher · View at Google Scholar · View at Scopus
  90. I. Vidlickova, F. Dequiedt, L. Jelenska et al., “Apoptosis-induced ectodomain shedding of hypoxia-regulated carbonic anhydrase IX from tumor cells: a double-edged response to chemotherapy,” BMC Cancer, vol. 16, p. 239, 2016. View at Publisher · View at Google Scholar · View at Scopus
  91. B. Z. Qian, H. Zhang, J. Li et al., “FLT1 signaling in metastasis-associated macrophages activates an inflammatory signature that promotes breast cancer metastasis,” The Journal of Experimental Medicine, vol. 212, no. 9, pp. 1433–1448, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Luttun, M. Tjwa, L. Moons et al., “Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1,” Nature Medicine, vol. 8, no. 8, pp. 831–840, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. N. S. Raikwar, K. Z. Liu, and C. P. Thomas, “N-terminal cleavage and release of the ectodomain of Flt1 is mediated via ADAM10 and ADAM 17 and regulated by VEGFR2 and the Flt1 intracellular domain,” PLoS One, vol. 9, no. 11, article e112794, 2014. View at Publisher · View at Google Scholar · View at Scopus
  94. F. Schelter, J. Kobuch, M. L. Moss et al., “A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor,” The Journal of Biological Chemistry, vol. 285, no. 34, pp. 26335–26340, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. Y. Yang, Y. Wang, X. Zeng et al., “Self-control of HGF regulation on human trophoblast cell invasion via enhancing c-Met receptor shedding by ADAM10 and ADAM17,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 8, pp. E1390–E1401, 2012. View at Publisher · View at Google Scholar · View at Scopus
  96. K. Chalupsky, I. Kanchev, O. Zbodakova et al., “ADAM10/17-dependent release of soluble c-Met correlates with hepatocellular damage,” Folia Biologica, vol. 59, no. 2, pp. 76–86, 2013. View at Google Scholar
  97. S. L. Organ and M. S. Tsao, “An overview of the c-MET signaling pathway,” Therapeutic Advances in Medical Oncology, vol. 3, Supplement 1, pp. S7–S19, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. M. A. Miller, M. J. Oudin, R. J. Sullivan et al., “Reduced proteolytic shedding of receptor tyrosine kinases is a post-translational mechanism of kinase inhibitor resistance,” Cancer Discovery, vol. 6, no. 4, pp. 382–399, 2016. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Van Schaeybroeck, M. Kalimutho, P. D. Dunne et al., “ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer,” Cell Reports, vol. 7, no. 6, pp. 1940–1955, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. R. S. Khanna, H. T. Le, J. Wang, T. C. Fung, and C. J. Pallen, “The interaction of protein-tyrosine phosphatase α (PTPα) and RACK1 protein enables insulin-like growth factor 1 (IGF-1)-stimulated Abl-dependent and -independent tyrosine phosphorylation of PTPα,” The Journal of Biological Chemistry, vol. 290, no. 15, pp. 9886–9895, 2015. View at Publisher · View at Google Scholar · View at Scopus
  101. K. Kapp, J. Siemens, H. U. Haring, and R. Lammers, “Proteolytic processing of the protein tyrosine phosphatase α extracellular domain is mediated by ADAM17/TACE,” European Journal of Cell Biology, vol. 91, no. 9, pp. 687–693, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. X. M. Zheng, R. J. Resnick, and D. Shalloway, “Mitotic activation of protein-tyrosine phosphatase α and regulation of its Src-mediated transforming activity by its sites of protein kinase C phosphorylation,” The Journal of Biological Chemistry, vol. 277, no. 24, pp. 21922–21929, 2002. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Ardini, R. Agresti, E. Tagliabue et al., “Expression of protein tyrosine phosphatase alpha (RPTPα) in human breast cancer correlates with low tumor grade, and inhibits tumor cell growth in vitro and in vivo,” Oncogene, vol. 19, no. 43, pp. 4979–4987, 2000. View at Publisher · View at Google Scholar
  104. B. Xie, J. Chen, B. Liu, and J. Zhan, “Klotho acts as a tumor suppressor in cancers,” Pathology Oncology Research, vol. 19, no. 4, pp. 611–617, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. H. Jin, Y. Pan, L. Zhao et al., “p75 neurotrophin receptor suppresses the proliferation of human gastric cancer cells,” Neoplasia, vol. 9, no. 6, pp. 471–478, 2007. View at Publisher · View at Google Scholar · View at Scopus
  106. X. J. Wang, C. W. Feng, and M. Li, “ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway,” Molecular and Cellular Biochemistry, vol. 380, no. 1-2, pp. 57–66, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. R. S. Cook, K. M. Jacobsen, A. M. Wofford et al., “MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis,” The Journal of Clinical Investigation, vol. 123, no. 8, pp. 3231–3242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  108. E. Thorp, T. Vaisar, M. Subramanian, L. Mautner, C. Blobel, and I. Tabas, “Shedding of the Mer tyrosine kinase receptor is mediated by ADAM17 protein through a pathway involving reactive oxygen species, protein kinase Cδ, and p38 mitogen-activated protein kinase (MAPK),” The Journal of Biological Chemistry, vol. 286, no. 38, pp. 33335–33344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. B. Cai, E. B. Thorp, A. C. Doran et al., “MerTK cleavage limits proresolving mediator biosynthesis and exacerbates tissue inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 113, no. 23, pp. 6526–6531, 2016. View at Publisher · View at Google Scholar · View at Scopus
  110. S. Sather, K. D. Kenyon, J. B. Lefkowitz et al., “A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation,” Blood, vol. 109, no. 3, pp. 1026–1033, 2007. View at Publisher · View at Google Scholar · View at Scopus
  111. H. Tye, C. L. Kennedy, M. Najdovska et al., “STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation,” Cancer Cell, vol. 22, no. 4, pp. 466–478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  112. J. C. Leemans, L. M. Butter, W. P. Pulskens et al., “The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury,” PLoS One, vol. 4, no. 5, article e5704, 2009. View at Publisher · View at Google Scholar · View at Scopus
  113. M. R. Dasu and R. R. Isseroff, “Toll-like receptors in wound healing: location, accessibility, and timing,” The Journal of Investigative Dermatology, vol. 132, no. 8, pp. 1955–1958, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. P. Langjahr, D. Diaz-Jimenez, M. De la Fuente et al., “Metalloproteinase-dependent TLR2 ectodomain shedding is involved in soluble toll-like receptor 2 (sTLR2) production,” PLoS One, vol. 9, no. 12, article e104624, 2014. View at Publisher · View at Google Scholar · View at Scopus
  115. T. Ishikawa and R. H. Kramer, “Sdc1 negatively modulates carcinoma cell motility and invasion,” Experimental Cell Research, vol. 316, no. 6, pp. 951–965, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. S. A. Ibrahim, H. Hassan, L. Vilardo et al., “Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling,” PLoS One, vol. 8, no. 12, article e85737, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. X. Wang, D. Zuo, Y. Chen et al., “Shed syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer,” British Journal of Cancer, vol. 111, no. 10, pp. 1965–1976, 2014. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Xu, P. W. Park, F. Kheradmand, and D. B. Corry, “Endogenous attenuation of allergic lung inflammation by syndecan-1,” The Journal of Immunology, vol. 174, no. 9, pp. 5758–5765, 2005. View at Publisher · View at Google Scholar
  119. E. Sanchez-Lopez, E. Flashner-Abramson, S. Shalapour et al., “Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling,” Oncogene, vol. 35, no. 20, pp. 2634–2644, 2016. View at Publisher · View at Google Scholar · View at Scopus
  120. D. Bilbao, L. Luciani, B. Johannesson, A. Piszczek, and N. Rosenthal, “Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease,” EMBO Molecular Medicine, vol. 6, no. 11, pp. 1423–1435, 2014. View at Publisher · View at Google Scholar · View at Scopus
  121. N. Hoa, S. Tsui, N. F. Afifiyan et al., “Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves’ disease: apparent role of ADAM17,” PLoS One, vol. 7, no. 4, article e34173, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. J. Wei, X. Qi, Q. Zhan et al., “miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression,” Biomedicine & Pharmacotherapy, vol. 71, pp. 112–118, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. Z. Yan, J. Jiang, F. Li et al., “Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin,” Oncology Reports, vol. 33, no. 4, pp. 1791–1798, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. W. Yi, C. Holmlund, J. Nilsson et al., “Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1,” Experimental Cell Research, vol. 317, no. 4, pp. 504–512, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. T. Nakamura, J. Hamuro, M. Takaishi et al., “LRIG1 inhibits STAT3-dependent inflammation to maintain corneal homeostasis,” The Journal of Clinical Investigation, vol. 124, no. 1, pp. 385–397, 2014. View at Publisher · View at Google Scholar · View at Scopus
  126. B. B. Zhou, M. Peyton, B. He et al., “Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer,” Cancer Cell, vol. 10, no. 1, pp. 39–50, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. W. Yao, J. Zhuo, D. M. Burns et al., “Discovery of a potent, selective, and orally active human epidermal growth factor receptor-2 sheddase inhibitor for the treatment of cancer,” Journal of Medicinal Chemistry, vol. 50, no. 4, pp. 603–606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  128. D. M. Burns, C. He, Y. Li et al., “Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle permutations,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 2, pp. 560–564, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. W. Yao, J. Zhuo, D. M. Burns et al., “Design and identification of selective HER-2 sheddase inhibitors via P1′ manipulation and unconventional P2′ perturbations to induce a molecular metamorphosis,” Bioorganic & Medicinal Chemistry Letters, vol. 18, no. 1, pp. 159–163, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. D. M. Burns, Y. L. Li, E. Shi et al., “Compelling P1 substituent affect on metalloprotease binding profile enables the design of a novel cyclohexyl core scaffold with excellent MMP selectivity and HER-2 sheddase inhibition,” Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 13, pp. 3525–3530, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. L. Li, E. Shi, D. Burns et al., “Discovery of novel selective HER-2 sheddase inhibitors through optimization of P1 moiety,” Bioorganic & Medicinal Chemistry Letters, vol. 19, no. 17, pp. 5037–5042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  132. J. B. H. Infante, N. Lewis, R. Donehower et al., “A multicenter phase Ib study of the safety, pharmacokinetics, biological activity and clinical efficacy of INCB7839, a potent and selective inhibitor of ADAM10 and ADAM17,” Breast Cancer Research and Treatment, vol. 106, article S269, Supplement1, 2007. View at Google Scholar
  133. D. Tural, E. Akar, H. Mutlu, and S. Kilickap, “P95 HER2 fragments and breast cancer outcome,” Expert Review of Anticancer Therapy, vol. 14, no. 9, pp. 1089–1096, 2014. View at Publisher · View at Google Scholar · View at Scopus
  134. M. J. Duffy, M. Mullooly, N. O'Donovan et al., “The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?” Clinical Proteomics, vol. 8, no. 1, p. 9, 2011. View at Publisher · View at Google Scholar · View at Scopus
  135. S. Hirata, T. Murata, D. Suzuki et al., “Selective inhibition of ADAM17 efficiently mediates glycoprotein Ibα retention during ex vivo generation of human induced pluripotent stem cell-derived platelets,” Stem Cells Translational Medicine, vol. 5, 2016. View at Publisher · View at Google Scholar
  136. D. Minond, M. Cudic, N. Bionda et al., “Discovery of novel inhibitors of a disintegrin and metalloprotease 17 (ADAM17) using glycosylated and non-glycosylated substrates,” The Journal of Biological Chemistry, vol. 287, no. 43, pp. 36473–36487, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. R. Stawikowska, M. Cudic, M. Giulianotti, R. A. Houghten, G. B. Fields, and D. Minond, “Activity of ADAM17 (a disintegrin and metalloprotease 17) is regulated by its noncatalytic domains and secondary structure of its substrates,” The Journal of Biological Chemistry, vol. 288, no. 31, pp. 22871–22879, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. A. M. Knapinska, D. Dreymuller, A. Ludwig et al., “SAR studies of exosite-binding substrate-selective inhibitors of a disintegrin and metalloprotease 17 (ADAM17) and application as selective in vitro probes,” Journal of Medicinal Chemistry, vol. 58, no. 15, pp. 5808–5824, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. C. H. Leung, L. J. Liu, L. Lu et al., “A metal-based tumour necrosis factor-alpha converting enzyme inhibitor,” Chemical Communications, vol. 51, no. 19, pp. 3973–3976, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. C. J. Tape, S. H. Willems, S. L. Dombernowsky et al., “Cross-domain inhibition of TACE ectodomain,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 14, pp. 5578–5583, 2011. View at Publisher · View at Google Scholar · View at Scopus
  141. F. Caiazza, P. M. McGowan, M. Mullooly et al., “Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells,” British Journal of Cancer, vol. 112, no. 12, pp. 1895–1903, 2015. View at Publisher · View at Google Scholar · View at Scopus
  142. Y. Huang, N. Benaich, C. Tape, H. F. Kwok, and G. Murphy, “Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation,” International Journal of Biological Sciences, vol. 10, no. 7, pp. 702–714, 2014. View at Publisher · View at Google Scholar · View at Scopus
  143. H. F. Kwok, K. A. Botkjaer, C. J. Tape, Y. Huang, J. McCafferty, and G. Murphy, “Development of a ‘mouse and human cross-reactive’ affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy,” Protein Engineering, Design and Selection, vol. 27, no. 6, pp. 179–190, 2014. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Ye, S. M. Yuen, G. Murphy, R. Xie, and H. F. Kwok, “Anti-tumor effects of a ‘human & mouse cross-reactive’ anti-ADAM17 antibody in a pancreatic cancer model in vivo,” European Journal of Pharmaceutical Sciences, vol. 5, p. 57, 2017. View at Publisher · View at Google Scholar
  145. T. Takayanagi, S. J. Forrester, T. Kawai et al., “Vascular ADAM17 as a novel therapeutic target in mediating cardiovascular hypertrophy and perivascular fibrosis induced by angiotensin II,” Hypertension, vol. 68, no. 4, pp. 949–955, 2016. View at Publisher · View at Google Scholar · View at Scopus
  146. L. Peng, K. Cook, L. Xu et al., “Molecular basis for the mechanism of action of an anti-TACE antibody,” mAbs, vol. 8, 2016. View at Publisher · View at Google Scholar · View at Scopus
  147. J. Rios-Doria, D. Sabol, J. Chesebrough et al., “A monoclonal antibody to ADAM17 inhibits tumor growth by inhibiting EGFR and non-EGFR-mediated pathways,” Molecular Cancer Therapeutics, vol. 14, no. 7, pp. 1637–1649, 2015. View at Publisher · View at Google Scholar · View at Scopus
  148. J. D. Leonard, F. Lin, and M. E. Milla, “Chaperone-like properties of the prodomain of TNFα-converting enzyme (TACE) and the functional role of its cysteine switch,” Biochemical Journal, vol. 387, Part 3, pp. 797–805, 2005. View at Publisher · View at Google Scholar · View at Scopus
  149. P. E. Gonzales, A. Solomon, A. B. Miller, M. A. Leesnitzer, I. Sagi, and M. E. Milla, “Inhibition of the tumor necrosis factor-α-converting enzyme by its pro domain,” The Journal of Biological Chemistry, vol. 279, no. 30, pp. 31638–31645, 2004. View at Publisher · View at Google Scholar · View at Scopus
  150. X. Li, Y. Yan, W. Huang, and Y. Yang, “The study of the inhibition of the recombinant TACE prodomain to endotoxemia in mice,” International Journal of Molecular Sciences, vol. 10, no. 12, pp. 5442–5454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. C. A. Buckley, F. N. Rouhani, M. Kaler, B. Adamik, F. I. Hawari, and S. J. Levine, “Amino-terminal TACE prodomain attenuates TNFR2 cleavage independently of the cysteine switch,” American Journal of Physiology - Lung Cellular and Molecular Physiology, vol. 288, no. 6, pp. L1132–L1138, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. I. Sagi, E. Wong, and R. Afik, “Variants of TACE pro-domain as TNF-A inhibitor and their medical use,” U.S. Patent 14/398,754, 2013.
  153. C. Adrain, M. Zettl, Y. Christova, N. Taylor, and M. Freeman, “Tumor necrosis factor signaling requires iRhom2 to promote trafficking and activation of TACE,” Science, vol. 335, no. 6065, pp. 225–228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  154. T. Maretzky, D. R. McIlwain, P. D. Issuree et al., “iRhom2 controls the substrate selectivity of stimulated ADAM17-dependent ectodomain shedding,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 28, pp. 11433–11438, 2013. View at Publisher · View at Google Scholar · View at Scopus
  155. X. Li, T. Maretzky, G. Weskamp et al., “iRhoms 1 and 2 are essential upstream regulators of ADAM17-dependent EGFR signaling,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 19, pp. 6080–6085, 2015. View at Publisher · View at Google Scholar · View at Scopus
  156. M. Dang, N. Armbruster, M. A. Miller et al., “Regulated ADAM17-dependent EGF family ligand release by substrate-selecting signaling pathways,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 24, pp. 9776–9781, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. A. G. Grieve, H. Xu, U. Kunzel, P. Bambrough, B. Sieber, and M. Freeman, “Phosphorylation of iRhom2 at the plasma membrane controls mammalian TACE-dependent inflammatory and growth factor signalling,” eLife, vol. 6, 2017. View at Publisher · View at Google Scholar
  158. K. Brandl, W. Tomisato, and B. Beutler, “Inflammatory bowel disease and ADAM17 deletion,” The New England Journal of Medicine, vol. 366, no. 2, p. 190, 2012. View at Publisher · View at Google Scholar
  159. D. C. Blaydon, P. Biancheri, W. L. Di et al., “Inflammatory skin and bowel disease linked to ADAM17 deletion,” The New England Journal of Medicine, vol. 365, no. 16, pp. 1502–1508, 2011. View at Publisher · View at Google Scholar · View at Scopus
  160. P. D. Issuree, T. Maretzky, D. R. McIlwain et al., “iRHOM2 is a critical pathogenic mediator of inflammatory arthritis,” The Journal of Clinical Investigation, vol. 123, no. 2, pp. 928–932, 2013. View at Publisher · View at Google Scholar · View at Scopus
  161. P. Boutet, S. Aguera-Gonzalez, S. Atkinson et al., “Cutting edge: the metalloproteinase ADAM17/TNF-α-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein,” The Journal of Immunology, vol. 182, no. 1, pp. 49–53, 2009. View at Publisher · View at Google Scholar
  162. F. Ren, J. Li, X. Jiang et al., “Plasma soluble Tim-3 emerges as an inhibitor in sepsis: sepsis contrary to membrane Tim-3 on monocytes,” Tissue Antigens, vol. 86, no. 5, pp. 325–332, 2015. View at Publisher · View at Google Scholar · View at Scopus
  163. J. Marczynska, A. Ozga, A. Wlodarczyk et al., “The role of metalloproteinase ADAM17 in regulating ICOS ligand–mediated humoral immune responses,” The Journal of Immunology, vol. 193, no. 6, pp. 2753–2763, 2014. View at Publisher · View at Google Scholar · View at Scopus
  164. B. R. Bang, S. J. Kim, H. Yagita, M. Croft, and Y. J. Kang, “Inhibition of 4-1BBL-regulated TLR response in macrophages ameliorates endotoxin-induced sepsis in mice,” European Journal of Immunology, vol. 45, no. 3, pp. 886–892, 2015. View at Publisher · View at Google Scholar · View at Scopus
  165. M. Schlegel, T. Granja, S. Kaiser et al., “Inhibition of neogenin dampens hepatic ischemia-reperfusion injury,” Critical Care Medicine, vol. 42, no. 9, pp. e610–e619, 2014. View at Publisher · View at Google Scholar · View at Scopus
  166. S. Dutting, M. Bender, and B. Nieswandt, “Platelet GPVI: a target for antithrombotic therapy?!,” Trends in Pharmacological Sciences, vol. 33, no. 11, pp. 583–590, 2012. View at Publisher · View at Google Scholar · View at Scopus
  167. D. Li, M. Masiero, A. H. Banham, and A. L. Harris, “The notch ligand JAGGED1 as a target for anti-tumor therapy,” Frontiers in Oncology, vol. 4, p. 254, 2014. View at Publisher · View at Google Scholar · View at Scopus
  168. X. Ju, X. Jiao, A. Ertel et al., “v-Src oncogene induces Trop2 proteolytic activation via cyclin D1,” Cancer Research, vol. 76, 2016. View at Publisher · View at Google Scholar · View at Scopus
  169. T. Martens, N. O. Schmidt, C. Eckerich et al., “A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo,” Clinical Cancer Research, vol. 12, no. 20, Part 1, pp. 6144–6152, 2006. View at Publisher · View at Google Scholar · View at Scopus
  170. S. Kim, U. J. Lee, M. N. Kim et al., “MicroRNA miR-199a∗ regulates the MET proto-oncogene and the downstream extracellular signal-regulated kinase 2 (ERK2),” The Journal of Biological Chemistry, vol. 283, no. 26, pp. 18158–18166, 2008. View at Publisher · View at Google Scholar · View at Scopus
  171. C. T. Cummings, D. Deryckere, H. S. Earp, and D. K. Graham, “Molecular pathways: MERTK signaling in cancer,” Clinical Cancer Research, vol. 19, no. 19, pp. 5275–5280, 2013. View at Publisher · View at Google Scholar · View at Scopus
  172. E. J. Gallagher and D. LeRoith, “The proliferating role of insulin and insulin-like growth factors in cancer,” Trends in Endocrinology & Metabolism, vol. 21, no. 10, pp. 610–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. E. J. Gallagher and D. LeRoith, “Minireview: IGF, insulin, and cancer,” Endocrinology, vol. 152, no. 7, pp. 2546–2551, 2011. View at Publisher · View at Google Scholar · View at Scopus
  174. B. Liu, Z. Guo, H. Dong et al., “LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2,” Brain Research, vol. 1611, pp. 93–100, 2015. View at Publisher · View at Google Scholar · View at Scopus